Maintenance therapy after first-line chemo for ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial compares a new drug called Rina-S with standard care to see if it helps keep ovarian cancer from coming back. It is for people who have finished their first round of platinum-based chemotherapy and are in remission or stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stage III or IV ovarian cancer (including primary peritoneal or fallopian tube cancer) with a high-grade serous or endometrioid subtype.
- You have completed 6 to 8 cycles of platinum-based chemotherapy, with or without bevacizumab (a drug that blocks blood vessel growth).
- You have either had surgery or are not a candidate for surgery as part of your treatment plan.
- After chemotherapy, you have achieved a complete response, no evidence of disease, partial response, or stable disease (if you took bevacizumab) or complete response or partial response (if you did not take bevacizumab).
- You have not previously taken a PARP inhibitor (a type of targeted therapy) or any antibody-drug conjugate (a type of targeted chemotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called Rina-S (with or without a blood vessel-blocking drug) compared to standard chemotherapy options for ovarian cancer that has come back after initial treatment. The goal is to see if Rina-S works better and is safer than current standard care.
This trial tests whether adding Rina-S to standard maintenance therapy helps prevent cancer from returning in people with recurrent platinum-sensitive ovarian cancer who have responded to second-line platinum-based chemotherapy.
This study tests whether adding a new pill (INCB123667) to the usual maintenance drug bevacizumab (Avastin) can keep ovarian cancer from coming back, compared to bevacizumab alone. It is for women who have finished their first chemo and are in remission or have stable disease.
This trial tests a new experimental drug (JPI-547) combined with bevacizumab (a targeted therapy) as maintenance treatment for recurrent ovarian cancer after initial response to platinum-based chemo. The goal is to see if this combination can keep the cancer from growing longer than standard care.
This trial tests whether a combination of medications (hydroxychloroquine, everolimus, and others) can help keep ovarian cancer from coming back after successful platinum chemotherapy plus Avastin. It is for people whose cancer responded well to their most recent chemo and who can continue Avastin maintenance.
This study tests a new maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have finished their first round of chemo and are showing good response. The goal is to see if this treatment helps delay the cancer from coming back.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.